Molecularly Targeted Therapy: Great Progress or Evil Cycle

Dobashi, Yoh

doi:10.4172/2167-7700.1000e113

Cited by 2 publications

(2 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 1 While targeted molecules show promising antitumor activities against cancers such as lymphomas and breast cancer, the current treatment landscape of NSCLC is a blueprint for survival benefits of targeted therapy based on patients' unique genomic profiles. 2 , 3 Compared to platinum‐based chemotherapy, tyrosine kinase inhibitors (TKIs) have been shown to at least double the progression‐free survival (PFS) and overall survival (OS) of patients with epidermal growth factor receptor ( EGFR )‐mutated NSCLC. 4 Since 2004, several EGFR‐TKIs have been approved for first‐line management of EGFR ‐mutated NSCLC.…”

Section: Introductionmentioning

confidence: 99%

Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs

Chang,

Wang,

Tseng

et al. 2023

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundDespite the well‐established efficacies of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC), there is limited real‐world evidence comparing their effectiveness according to patients’ clinical characteristics. This network meta‐analysis (NMA) compared survival outcomes among first‐line EGFR‐TKIs in different subgroups of East Asian patients with advanced NSCLC.MethodsThis NMA included real‐world observational studies reporting outcomes with TKIs in patients aged >65 years, with baseline brain metastasis, with different Eastern Cooperative Oncology Group (ECOG) statuses, or with different common EGFR mutation types.ResultsIn patients with the EGFR L858R mutation, afatinib resulted in significantly longer progression‐free survival (PFS) than erlotinib (hazard ratio [HR]: 0.59, 95% confidence interval [CI]: 0.46–0.75) and gefitinib (HR: 0.41, 95% CI: 0.32–0.53). Similarly, in patients with the EGFR Del19 mutation, afatinib and erlotinib resulted in significantly longer PFS than gefitinib (HR: 0.48 with 95% CI: 0.33–0.71 and HR: 0.54 with 95% CI: 0.36–0.80, respectively). Moreover, afatinib resulted in significantly longer PFS than gefitinib in patients with brain metastasis (HR: 0.53, 95% CI: 0.33–0.87) or ECOG status 0–1 (HR: 0.37, 95% CI: 0.23–0.59).ConclusionThis NMA suggests that afatinib results in similar PFS to erlotinib and superior PFS than gefitinib in patients with Del19 mutant NSCLC, aged ≥65 years, with ECOG scores of 0–1, and with baseline brain metastasis.

show abstract

Section: Introductionmentioning

confidence: 99%

Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs

Chang,

Wang,

Tseng

et al. 2023

Thoracic Cancer

View full text Add to dashboard Cite

show abstract

“…3 Several types of targeted therapies exist, including small molecules, monoclonal antibodies and cancer vaccines. 4 The current treatment landscape of non-small-cell lung cancer (NSCLC) represents a blueprint for the survival benefits targeted therapy can provide according to the unique genomic profile of the patients; 5 pivotal clinical trials showed that targeted molecules doubled the survival of patients with NSCLC. 6,7 The evolution of precision medicine in NSCLC opened the gate for investigating the feasibility of targeted therapy in other cancer types.…”

Section: Introductionmentioning

confidence: 99%

Clinical experience with pemigatinib for previously treated metastatic cholangiocarcinoma: practical considerations from clinical cases

Wadsley¹,

Christie²,

Gillmore³

et al. 2023

DIC

View full text Add to dashboard Cite

The management of advanced cholangiocarcinoma (CCA) is challenging. In patients with advanced CCA, gemcitabine/cisplatin combination is the standard frontline chemotherapy, with 5-fluorouracil-based regimens preserved for subsequent lines; however, the expected survival is poor. Pemigatinib was approved for locally advanced or metastatic CCA with FGFR2 fusions or rearrangement. Pemigatinib has a manageable safety profile and achieves a durable response. Nearly 50 patients with CCA have been treated with pemigatinib in the United Kingdom. However, clinical experience with pemigatinib is lacking. We present our experience with three clinical cases to illustrate the position of pemigatinib in the management of CCA and related toxicities.

show abstract

Molecularly Targeted Therapy: Great Progress or Evil Cycle

Cited by 2 publications

References 6 publications

Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs

Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs

Clinical experience with pemigatinib for previously treated metastatic cholangiocarcinoma: practical considerations from clinical cases

Contact Info

Product

Resources

About